Physician profile
Rahat Salamat
NPI 1629173240
$3,866.85
in general payments reported to CMS, 2019-2025
21 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $495 · 2021: $545 · 2022: $306 · 2023: $294 · 2024: $375 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Travel and Lodging: $843 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.82 |
| Travel and Lodging | $843.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,167.78 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $487.42 | 2019-2023 | Arexvy |
| Harmony Biosciences LLC | $474.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.18 | 2019-2025 | Fasenra, Tezspire |
| Jazz Pharmaceuticals INC. | $205.52 | 2019-2023 | |
| Genzyme Corporation | $147.11 | 2021-2023 | |
| Insmed, INC. | $133.37 | 2020-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $132.92 | 2024 | Lumryz |
| Mylan Specialty L.P. | $126.35 | 2019-2021 | |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.32 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $70.14 | 2019-2023 | Prolastin-C Liquid |
| Abiomed | $42.76 | 2025 | |
| Sunovion Pharmaceuticals INC. | $40.76 | 2019-2020 | |
| Advanced Respiratory, INC | $34.06 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $31.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $17.63 | 2020 | |
| Philips North America LLC | $15.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.30 | 2020 | |
| Inogen, INC. | $6.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahat Salamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.